

Curriculum Vitae

Personal information Sylvie Morgeaux

Work experience

- 1. Employer: ANSM
 - Start date: 091995

 - End date: Position: Scientist
 - Position: Scientist
 Activities: In charge of vaccines release: Rabies, HAV, Smallpox, Malaria, DTaP,
 DTaP_HepB_Hib In charge of immunoglobulins: anti_vaccine and equine anti_rabies Other experiences in OPV, IPV, HBV and in most of viral vaccines Evaluation of the pharmaceutical part of MA: IPV, OPV, HAV, HBV, Rabies, Varicella, Shingles, Tick Born and Japanesse Encephalitis, Rotavirus, Papillomavirus, Smallpox, Ebola and for viral safety (Influenza, Dengue, Meningococcal B, Ebola) Expert in group15 of Eur. Ph and in Vaccine Drafting group Expert for WHO Project Leader for collaborative studies and PTS In charge of subjects related to the 3Rs strategy
- Country: France
 Employer: Pasteur Institute Paris
- - Start date: 101993 End date: 121994
 - Position: Research engineer
 - Activities: Study of immunological properties of new polysaccharide particles linked with
 - rabies antigens Country: France

Education and training

- 1. Subject: Pasteur Institute Paris
 - Start date: 121988 End date: 111992
 - Qualification: PhD
 - Organisation: Rabies vaccine controls: use of molecular biology and cellular immunology techniques to evaluate potency tests, humoral and cellular immunity, detection of residual cell
 - Country: France

Additional information

Publications

PUBLICATIONS Control/vaccine potency IPV, OPV, HAV and aP: 11 Viral safety and cellular residual DNA on vaccines: 3 Potency and immunity of rabies vaccines and immunoglobulins: 10 Molecular genetics and vaccinology: 1 3Rs strategy: 2 ÓRAL COMMUNÍCATIONS Control/vaccine potency IPV, OPV and YF:3 Viral safety and cellular residual DNA on vaccines: 3 Potency and immunity of rabies vaccines and immunoglobulins: 10 Vaccine regulation:

Projects

Collaboratives studies/biologicals standardization, proficiency techniques studies for vaccines: for WHO (4), EDQM as Project Leader (11) Project management on vaccine potency assays: design, development and implementation for

Memberships

European Pharmacopoeia (group 15 for human vaccines) and EDQM Council of Europe (Drafating group for human vaccine) during 9 years WHO ECBS during 4 years Technical committee of EPAA

Other Relevant Information

Assesment/training of National Regulatory Authorities: _ for WHO: 11 assessments, 5 training on sites, 2 GLO courses Coaching trainees: WHO (18), Europe (6), National (2) Involved in the 3Rs strategy in vaccine field Staff management animation of groups ISO 17025 audit for accreditation Organization of training, congresses Supervision